In preclinical breast cancer models with varying HER2 expression, Al-Saden et al. demonstrated that this tracer shows high HER2 specificity, comparable to [89Zr]Zr-DFO-trastuzumab, and is particularly effective at stratifying HER2 status at 4 days post-injection [60]. Here, ERBB2 is linked to breast carcinoma.